Navigation Links
Researchers identify genes that may help in ovarian cancer diagnosis and prognosis
Date:4/9/2012

Philadelphia, PA, April 9, 2012 Scientists from Duke University Medical Center have determined that genes acting as molecular "on/off" switches can define clinically relevant molecular subtypes of ovarian cancer, providing ideal potential targets for use in clinical prognostic and diagnostic testing. These bimodal genes can define tumor subtypes that have different overall prognoses and respond to different therapeutic regimens. The researchers' results are published in the May issue of The Journal of Molecular Diagnostics.

"We identified a very small set of genes that have the potential to be robust prognostic markers in epithelial ovarian cancer," explains lead investigator Michael B. Datto, MD, PhD. "We also demonstrated the utility of a novel approach, bimodal gene discovery, in identifying clinically relevant expression targets."

Ovarian carcinoma has the highest mortality rate among gynecologic malignancies and is the fifth most common cause of cancer death in women. Prognostic methods for serous carcinomas, the most common type of epithelial ovarian malignancy, remain relatively inaccurate. The majority of patients present with high-grade, late-stage tumors and have an overall poor prognosis. Within this group, however, there is a subset with durable response to chemotherapy, resulting in better survival. There are currently no tests in general use that can distinguish tumors that may be more effectively treated.

Based on early work in breast cancer, Dr. Datto and his colleagues hypothesized that clinically relevant bimodal genes exist in epithelial ovarian cancer. Using a large, publically available ovarian cancer microarray dataset, they applied a previously described biomodal index discovery algorithm to evaluate the expression of all genes across 285 samples. They identified many genes with robust patterns of bimodal expression. They also found that a number of genes with bimodal expression patterns are significantly associated with tumor type and/or overall patient survival. When combined into a single sum survival score, the top survival-significant genes identify a clinically distinct molecular subtype of malignant serous ovarian carcinoma.

"From a clinical testing perspective, genes with a continuous pattern of expression can make difficult testing targets. However, the distinction between 'on' or 'off' expression for a particular bimodal gene is relatively straightforward," says Dr. Datto. "This allows clear-cut decision making boundaries and development of precise, reliable testing methods. Bimodal genes may also be candidates for testing by less quantitative methods such as immunohistochemistry."

Several of the bimodal genes that the researchers identified have known roles in tumorigenesis. "This raises the possibility that we have described molecular switch genes that will not only be relevant in the context of ovarian carcinoma, but across multiple tumor types," Dr. Datto concludes.


'/>"/>
Contact: David Sampson
jmdmedia@elsevier.com
215-239-3171
Elsevier Health Sciences
Source:Eurekalert

Related biology news :

1. Researchers use game to change how scientists study disease outbreaks
2. Notre Dame researchers using novel method to combat malaria drug resistance
3. BU researchers derive purified lung and thyroid progenitors from embryonic stem cells
4. Researchers report potential for a moderate New England red tide in 2012
5. Tales from the crypt lead researchers to cancer discovery
6. Researchers identify new regulator in allergic diseases
7. WHOI researchers, collaborators receive $1.4 million grant to study life in oceans greatest depths
8. Researchers unravel genetic mechanism of fatty liver disease in obese children
9. Montreal researchers repel mortality in Malian mothers
10. UF researchers look for ways to make an emerging technology safe for environment
11. UCSB researchers to examine the effects of year-old NOAA West Coast Catch Shares program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2016)... and LONDON , April 26, ... of EdgeVerve Systems, a product subsidiary of Infosys ... announced a partnership to integrate the Onegini mobile ...      (Logo: http://photos.prnewswire.com/prnh/20151104/283829LOGO ) ... customers enhanced security to access and transact across ...
(Date:4/14/2016)... TEL AVIV, Israel , April 14, 2016 /PRNewswire/ ... in Behavioral Authentication and Malware Detection, today announced the ... has already assumed the new role. Goldwerger,s ... for BioCatch, on the heels of the deployment of ... In addition, BioCatch,s behavioral biometric technology, which discerns unique ...
(Date:3/23/2016)... , March 23, 2016 ... erhöhter Sicherheit Gesichts- und Stimmerkennung mit Passwörtern ... (NASDAQ: MESG ), ein führender ... das Unternehmen mit SpeechPro zusammenarbeitet, um erstmals ... Finanzdienstleistungsbranche, wird die Möglichkeit angeboten, im Rahmen ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... - BIOREM Inc. (TSX-V: BRM) ("Biorem" or "the Company") announces ... Clean Technology Fund I, LP and Clean Technology Fund ... venture capital funds which together hold approximately 59% of ... as converted basis), that they have entered into an ... in Biorem to TUS Holdings Co. Ltd. ("TUS") (en.tusholdings.com) ...
(Date:6/27/2016)... ... 27, 2016 , ... Rolf K. Hoffmann, former senior vice ... University of North Carolina Kenan-Flagler Business School effective June 27. , ... with a focus on the school’s international efforts, leading classes and participating in ...
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial spectrophotometers and ... and the 6000i models are higher end machines that use the more unconventional z-dimension ... light beam from the bottom of the cuvette holder. , FireflySci has developed ...
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT has ... Ontario biotechnology company, Propellon Therapeutics Inc. ... and commercialization of a portfolio of first-in-class WDR5 ... targets such as WDR5 represent an exciting class ... in precision medicine for cancer patients. Substantial advances ...
Breaking Biology Technology: